BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYED) (“Skye” or the “Company”), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes

GeneDx announced that, effective as of October 1, the compensation committee of GeneDx’s board of directors granted newly-hired employees 133,998 restricted stock units as inducements material to each employee entering into employment with GeneDx.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.

Kestra Medical Technologies is launching the ASSURE Clinician Experience (ACE), a program that lets electrophysiology and cardiology professionals wear and simulate use of the ASSURE® Wearable Cardioverter Defibrillator (WCD) system at The Heart Rhythm Society #HRX2023 global health and technology conference, September 21-23, 2023 in Seattle, WA.

Brandon Cuevas has been selected as executive vice president for Kaiser Foundation Health Plan with national accountability for health plan strategy, capabilities, and operations, effective October 1, 2023.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model.

Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company’s bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization.

Soligenix, Inc. announced that its 2023 Annual Meeting of Stockholders scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 7, 2023.

Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, announced that it will effect a 1-for-15 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, September 25, 2023.

Matinas BioPharma announced that it has received a deficiency letter from NYSE American LLC stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide.